Anne Ortved Gang

Medicine & Life Sciences

1. Lymphoma, Large B-Cell, Diffuse 100%
2. Lymphoma 77%
3. B-Cell Lymphoma 65%
4. Non-Hodgkin's Lymphoma 39%
5. Survival 32%
6. T-Lymphocytes 30%
7. Multiple Myeloma 29%
8. Follicular Lymphoma 26%
9. Peripheral T-Cell Lymphoma 24%
10. Population 22%
11. B-Cell Chronic Lymphocytic Leukemia 21%
12. Etoposide 21%
13. Survivors 20%
14. Therapeutics 20%
15. Azacitidine 19%
16. Neoplasms 18%
17. Vaccines 18%
18. Vaccination 17%
19. R-CHOP protocol 17%
20. SARS Virus 16%
21. Rituximab 15%
22. Progression-Free Survival 14%
23. Denmark 13%
24. High-Throughput Nucleotide Sequencing 13%
25. Genetic Heterogeneity 13%
26. Myeloid-Derived Suppressor Cells 13%
27. Agammaglobulinaemia Tyrosine Kinase 13%
28. Cohort Studies 12%
29. B-Lymphocytes 12%
30. Epitope Mapping 12%
31. Endogenous Retroviruses 12%
32. Cancer Vaccines 11%
33. Immunoglobulin Heavy Chains 11%
34. Epitopes 11%
35. Regulatory T-Lymphocytes 11%
36. Myelodysplastic Syndromes 11%
37. Genes 11%
38. Hodgkin Disease 11%
39. Dendritic Cells 10%
40. Clinical Trials, Phase I 10%
41. T-Lymphocyte Epitopes 10%
42. Hematology 10%
43. Fluorescence In Situ Hybridization 10%
44. Return to Work 10%
45. Peptides 10%
46. Doxorubicin 10%
47. Adoptive Transfer 10%
48. Hematologic Neoplasms 10%
49. Biomarkers 10%
50. Drug Therapy 10%